Literature DB >> 12472946

Pathogenesis of hepatic encephalopathy.

Dieter Häussinger1, Freimut Schliess, Gerald Kircheis.   

Abstract

Hepatic encephalopathy (HE) is a neuropsychiatric syndrome during the course of acute or chronic liver disease. It is functional in nature, potentially reversible and precipitated by rather heterogeneous factors. At the neurophysiological level HE is characterized by a low frequent cortico-cortical electrical coupling, which may explain the cognitive deficits and a low frequent corticomuscular coupling, which may explain the fine motor deficits. Current evidence suggests that HE is the consequence of a low grade chronic glial edema with subsequent alterations of glioneuronal communication. Different factors, such as ammonia, benzodiazepines, inflammatory cytokines can induce or aggravate astrocyte swelling, which results in the activation of osmosignaling cascades, protein modifications, alterations in gene expression and neurotransmission. Among the protein modifications nitration of critical tyrosine residues in glial proteins may play an important role. Several proteins, which are nitrated in response to ammonia, benzodiazepines, hypoosmotic astrocyte swelling or inflammatory cytokines have been identified, including glutamine synthetase and the peripheral type benzodiazepine receptor. Copyright 2002 Blackwell Publishing Asia Pty Ltd

Entities:  

Mesh:

Year:  2002        PMID: 12472946     DOI: 10.1046/j.1440-1746.17.s3.10.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  10 in total

Review 1.  The extrahepatic consequences of cirrhosis.

Authors:  Jin Kee Ho; Eric Yoshida
Journal:  MedGenMed       Date:  2006-03-02

2.  GABAA-receptor modification in taurine transporter knockout mice causes striatal disinhibition.

Authors:  O A Sergeeva; W Fleischer; A N Chepkova; U Warskulat; D Häussinger; M Siebler; H L Haas
Journal:  J Physiol       Date:  2007-10-25       Impact factor: 5.182

Review 3.  The role of magnetic resonance imaging and spectroscopy in hepatic encephalopathy.

Authors:  Mark J W McPhail; Simon D Taylor-Robinson
Journal:  Metab Brain Dis       Date:  2010-03-11       Impact factor: 3.584

4.  Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy: a comparative study of 154 patients with liver disease.

Authors:  Mette Munk Lauridsen; Peter Jepsen; Hendrik Vilstrup
Journal:  Metab Brain Dis       Date:  2011-04-12       Impact factor: 3.584

5.  Gender and age effects on the continuous reaction times method in volunteers and patients with cirrhosis.

Authors:  Mette Munk Lauridsen; Henning Grønbæk; Esben B Næser; Steffen T Leth; Hendrik Vilstrup
Journal:  Metab Brain Dis       Date:  2012-05-22       Impact factor: 3.584

Review 6.  The continuous reaction times method for diagnosing, grading, and monitoring minimal/covert hepatic encephalopathy.

Authors:  M M Lauridsen; M Thiele; N Kimer; H Vilstrup
Journal:  Metab Brain Dis       Date:  2013-01-10       Impact factor: 3.584

7.  Histamine receptor expression, hippocampal plasticity and ammonia in histidine decarboxylase knockout mice.

Authors:  Aisa Chepkova; Evgenij Yanovsky; Regis Parmentier; Hiroshi Ohtsu; Helmut L Haas; Jian-Sheng Lin; Olga A Sergeeva
Journal:  Cell Mol Neurobiol       Date:  2011-06-28       Impact factor: 5.046

Review 8.  Sodium-coupled neutral amino acid (System N/A) transporters of the SLC38 gene family.

Authors:  Bryan Mackenzie; Jeffrey D Erickson
Journal:  Pflugers Arch       Date:  2003-07-04       Impact factor: 3.657

9.  Connectivity of default-mode network is associated with cerebral edema in hepatic encephalopathy.

Authors:  Wei-Che Lin; Tun-Wei Hsu; Chao-Long Chen; Changwei W Wu; Cheng-Hsien Lu; Hsiu-Ling Chen; Shau-Hsuan Li; Pin-Yang Yeh; Yu-Fan Cheng; Ching-Po Lin
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

10.  Pathogenesis of hepatic encephalopathy.

Authors:  Irena Ciećko-Michalska; Małgorzata Szczepanek; Agnieszka Słowik; Tomasz Mach
Journal:  Gastroenterol Res Pract       Date:  2012-12-17       Impact factor: 2.260

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.